Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preseasonal Omalizumab in Seasonal Allergic Rhinitis
NCT04489121Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of omalizumab in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: change of total nasal symptoms scores at week 6 and Rescue medication score at week 6. Started Jul 2020; status: completed.
02
Drugs
omalizumab
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT04489121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489121.